Robert Sidonio

List of Publications by Year
in descending order

113 papers	1,985 citations	257101 24 h-index	288905 40 g-index
113 all docs	113 docs citations	113 times ranked	1729 citing authors

#	Article	IF	Citations
1	Successful Perioperative Management of Orthotopic Cardiac Transplantation in a Pediatric Patient With Concurrent Congenital von Willebrand Disease and Acquired von Willebrand Syndrome Using Recombinant von Willebrand Factor. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 724-727.	0.6	2
2	Whole-exome analysis of adolescents with low VWF and heavy menstrual bleeding identifies novel genetic associations. Blood Advances, 2022, 6, 420-428.	2.5	4
3	Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2022, 327, 129.	3.8	37
4	International consensus recommendations on the management of people with haemophilia B. Therapeutic Advances in Hematology, 2022, 13, 204062072210852.	1.1	13
5	Managing Severe Hemophilia A in Children: Pharmacotherapeutic Options. Pediatric Health, Medicine and Therapeutics, 2022, Volume 13, 27-35.	0.7	6
6	Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements. Journal of Managed Care & Specialty Pharmacy, 2022, 28, 518-527.	0.5	2
7	OP031: The emotional experience of hemophilia heterozygote women: Average maternal guilt, effective coping strategies, and resilience within the hemophilia community. Genetics in Medicine, 2022, 24, S359-S360.	1.1	0
8	Bone health in haemophilia carriers and persons with von Willebrand disease: A large database analysis. Haemophilia, 2022, 28, 671-678.	1.0	5
9	Health issues in women and girls affected by haemophilia with a focus on nomenclature, heavy menstrual bleeding, and musculoskeletal issues. Haemophilia, 2022, 28, 18-25.	1.0	10
10	â€œA New Hemophilia Carrier Nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTHâ€: Reply to comment. Journal of Thrombosis and Haemostasis, 2022, 20, 1745-1746.	1.9	0
11	Substitution therapy. Haemophilia, 2021, 27, 53-59.	1.0	7
12	Discussing investigational AAV gene therapy with hemophilia patients: A guide. Blood Reviews, 2021, 47, 100759.	2.8	40
13	Emicizumab in tolerized patients with hemophilia A with inhibitors: A singleâ€institution pediatric cohort assessing inhibitor status. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 342-348.	1.0	13
14	Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. Haemophilia, 2021, 27, 211-220.	1.0	3
15	COVID-19 Cliff Notes: A COVID-19 Multidisciplinary Care Compendium. Transplantation and Cellular Therapy, 2021, 27, 474.e1-474.e3.	0.6	1
16	Occurrence rates of von Willebrand disease among people receiving care in specialized treatment centres in the United States. Haemophilia, 2021, 27, 445-453.	1.0	13
17	Elevated von Willebrand factor levels during heavy menstrual bleeding episodes limit the diagnostic utility for von Willebrand disease. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12513.	1.0	15
18	Plasma factor IX: The tip of the iceberg?. Haemophilia, 2021, 27, 329-331.	1.0	1

#	Article	IF	Citations
19	A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2021, 19, 1883-1887.	1.9	59
20	Women and girls with haemophilia receiving care at specialized haemophilia treatment centres in the United States. Haemophilia, 2021, 27, 1037-1044.	1.0	14
21	Hemophilia B (Factor IX Deficiency). Hematology/Oncology Clinics of North America, 2021, 35, 1143-1155.	0.9	6
22	Bleeding assessment tools in the diagnosis of VWD in adults and children: a systematic review and meta-analysis of test accuracy. Blood Advances, 2021, 5, 5023-5031.	2.5	6
23	ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Advances, 2021, 5, 280-300.	2.5	246
24	Design of an international investigator-initiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A (MOTIVATE). Therapeutic Advances in Hematology, 2021, 12, 204062072110324.	1.1	6
25	Women and girls with haemophilia and bleeding tendencies: Outcomes related to menstruation, pregnancy, surgery and other bleeding episodes from a retrospective chart review. Haemophilia, 2021, 27, 293-304.	1.0	15
26	The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia, 2021, 27, 921-931.	1.0	7
27	von Willebrand disease: proposing definitions for future research. Blood Advances, 2021, 5, 565-569.	2.5	5
28	Bleeding patterns in patients before and after diagnosis of von Willebrand disease: Analysis of a US medical claims database. Haemophilia, 2021, , .	1.0	5
29	Immunogenicity, Efficacy and Safety of Rurioctocog Alfa Pegol in Previously Untreated Patients with Severe Hemophilia a: Interim Results from an Open-Label Multicenter Clinical Trial. Blood, 2021, 138, 3184-3184.	0.6	2
30	Prevalence of Acute and Chronic Migraine Among Patients with Von Willebrand Disease. Blood, 2021, 138, 4245-4245.	0.6	0
31	A Multi-Institution Retrospective Study to Assess Bleeding Phenotype Among Patients with Platelet Function Disorders. Blood, 2021, 138, 3033-3033.	0.6	0
32	Depression and Anxiety in Persons with Von Willebrand Disease. Blood, 2021, 138, 4052-4052.	0.6	2
33	Assessment of TRM-201 (Rofecoxib) Efficacy and Safety for Chronic Pain in Hemophilic Arthropathy: The Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy (RESET-HA), a Randomized, Double-Blind Placebo-Controlled Phase III Clinical Trial. Blood, 2021, 138, 4243-4243.	0.6	0
34	Bleeding in Patients with Clinically Severe Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe Von Willebrand Disease (VWD). Blood, 2021, 138, 3183-3183.	0.6	0
35	Rurioctocog Alfa Pegol Use in Immune Tolerance Induction: Interim Results from an Open-Label Multicenter Clinical Trial in Previously Untreated Patients with Severe Hemophilia a. Blood, 2021, 138, 3185-3185.	0.6	0
36	Surgery-Associated Bleeding Risk in Patients with Platelet Function Disorders - a Cross Sectional Study with the American Thrombosis and Hemostasis Network Dataset (ATHNdataset). Blood, 2021, 138, 180-180.	0.6	0

#	Article	IF	Citations
37	Real-World Data of the Hemostatic Efficacy of Recombinant Human Factor VIIa Eptacog Beta for Acute Bleeding Events in Patients with Hemophilia a and B with Inhibitors. Blood, 2021, 138, 4246-4246.	0.6	0
38	PREDICT: A Multicenter, Prospective, Open-Label, Clinical Study Using a New Risk Score Approach to Assess the Most Appropriate Prophylaxis Regimen to Reach Favorable Outcomes in Hemophilia A, When Switching from Standard-Half-Life Products to Damoctocog Alfa Pegol. Blood, 2021, 138, 2115-2115.	0.6	0
39	A Cross-Sectional Study of Women and Girls with Congenital Bleeding Disorders: The American Thrombosis and Hemostasis Network Cohort. Journal of Women's Health, 2020, 29, 670-676.	1.5	12
40	An international survey to inform priorities for new guidelines on von Willebrand disease. Haemophilia, 2020, 26, 106-116.	1.0	32
41	Healthâ€related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitorsâ€”Results from the HAVEN 2 study. Haemophilia, 2020, 26, 1009-1018.	1.0	16
42	The spectrum and severity of bleeding in adolescents with low von Willebrand factorâ€“associated heavy menstrual bleeding. Blood Advances, 2020, 4, 3209-3216.	2.5	17
43	Incidence and Timing of Thrombosis After the Norwood Procedure in the Singleâ€Ventricle Reconstruction Trial. Journal of the American Heart Association, 2020, 9, e015882.	1.6	5
44	The impact of extended halfâ€life factor concentrates on prophylaxis for severe hemophilia in the United States. American Journal of Hematology, 2020, 95, 960-965.	2.0	19
45	Laboratory misdiagnosis of von Willebrand disease in <scp>postâ€menarchal</scp> females: A <scp>multiâ€center</scp> study. American Journal of Hematology, 2020, 95, 1022-1029.	2.0	15
46	Spontaneous bleeding and poor bleeding response with extended halfâ€life factor IX products: A survey of select US haemophilia treatment centres. Haemophilia, 2020, 26, e128-e129.	1.0	19
47	Potential Undiagnosed VWD Or Other Mucocutaneous Bleeding Disorder Cases Estimated From Private Medical Insurance Claims . Journal of Blood Medicine, 2020, Volume 11, 1-11.	0.7	11
48	Characterizing female patients with haemophilia A: Administrative claims analysis and medical chart review. Haemophilia, 2020, 26, 520-528.	1.0	5
49	Hemophilia Carriers. , 2020, , 43-50.		0
50	Healthcare Utilization and Health Related Quality of Life in Persons with Von Willebrand Disease. Blood, 2020, 136, 3-4.	0.6	2
51	Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis. Haemophilia, 2019, 25, 789-796.	1.0	59
52	Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events. Journal of Medical Economics, 2019, 22, 1328-1337.	1.0	15
53	Correlations between patient-reported outcomes and self-reported characteristics in adults with hemophilia B and caregivers of children with hemophilia B: analysis of the B-HERO-S study . Patient Related Outcome Measures, 2019, Volume 10, 299-314.	0.7	3
54	TFPI blockade: removing coagulationâ€™s brakes. Blood, 2019, 134, 1885-1887.	0.6	4

#	Article	IF	Citations
55	A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood, 2019, 134, 2127-2138.	0.6	241
56	Aberrant splicing contributes to severe Î±-spectrinâ€“linked congenital hemolytic anemia. Journal of Clinical Investigation, 2019, 129, 2878-2887.	3.9	24
57	Spontaneous Bleeding and Poor Bleeding Response with Extended Half-Life Factor IX Products: A Survey of Select US and Canadian Hemophilia Treatment Centers. Blood, 2019, 134, 2407-2407.	0.6	6
58	Thrombotic Outcomes Following Hormonal Treatment of Heavy Menstrual Bleeding in Pediatric Patients Taking Anticoagulation. Blood, 2019, 134, 2179-2179.	0.6	1
59	Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial. Blood, 2019, 134, 1130-1130.	0.6	1
60	Analysis of Bleeding and Treatment Patterns in Children and Adolescents before and after Von Willebrand Disease Diagnosis Using Data from a US Medical Claims Database. Blood, 2019, 134, 2117-2117.	0.6	0
61	Severe Bleeding Events in Hemophilia Î‘ Patients Receiving Emicizumab Prophylaxis. Blood, 2019, 134, 1126-1126.	0.6	3
62	The Discordance between Offsite to Onsite Testing for Von Willebrand Disease in Post-Menarchal Females: A Multi-Center Study. Blood, 2019, 134, 628-628.	0.6	0
63	Obtaining a Von Willebrand Evaluation at Time of Acute Heavy Menstrual Bleeding Presentation Leads to Overestimation of Von Willebrand Levels. Blood, 2019, 134, 627-627.	0.6	0
64	Clinical Study to Investigate the Efficacy and Safety of Wilate during Prophylaxis in Previously Treated Patients with Von Willebrand Disease (VWD). Blood, 2019, 134, 4931-4931.	0.6	0
65	Assessing the Safety of Various VWF Regimens in Patients with Clinically Severe VWD: A Natural History Study. Blood, 2019, 134, 1132-1132.	0.6	4
66	Lack of Inhibitor Development in the American Thrombosis and Hemostasis Network (ATHN)-2 Factor Switching Study: Preliminary Report of Primary Outcome. Blood, 2019, 134, 1114-1114.	0.6	1
67	Impact of hemophilia B on quality of life in affected men, women, and caregiversâ€”Assessment of patientâ€reported outcomes in the Bâ€<scp>HERO</scp>â€s study. European Journal of Haematology, 2018, 100, 592-602.	1.1	30
68	Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States. Journal of Medical Economics, 2018, 21, 762-769.	1.0	10
69	Acquired Hypofibrinogenemia Before Asparaginase Exposure During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia: A Report of 2 Cases and Review of the Literature. Journal of Pediatric Hematology/Oncology, 2018, 40, e470-e472.	0.3	4
70	Relevance of Abusive Head Trauma to Intracranial Hemorrhages and Bleeding Disorders. Pediatrics, 2018, 141, e20173485.	1.0	15
71	The spectrum of bleeding in women and girls with haemophilia B. Haemophilia, 2018, 24, 180-185.	1.0	15
72	Reliability and validity of patientâ€reported outcome instruments in US adults with hemophilia B and caregivers in the Bâ€HEROâ€s study. European Journal of Haematology, 2018, 101, 781-790.	1.1	7

#	Article	IF	Citations
73	A decreased and less sustained desmopressin response in hemophilia A carriers contributes to bleeding. Blood Advances, 2018, 2, 2629-2636.	2.5	15
74	Novel therapeutics for hemophilia and other bleeding disorders. Blood, 2018, 132, 23-30.	0.6	46
75	A crossâ€sectional study of nonâ€attendance among patients at a <scp>US</scp> hemophilia treatment center 2010â€2014. Haemophilia, 2018, 24, 902-910.	1.0	4
76	Prospective Diagnosis of VWD in a Large Cohort of Patients with Bleeding Symptoms through the Zimmerman Program. Blood, 2018, 132, 979-979.	0.6	1
77	Real World Use of Extended Half-Life Products and the Impact on Bleeding Events and Joint Health in the United States. Blood, 2018, 132, 1195-1195.	0.6	1
78	The Atlanta Protocol: Immune Tolerance Induction in Pediatric Patients with Hemophilia a and Inhibitors on Emicizumab. Blood, 2018, 132, 634-634.	0.6	2
79	Model of the Impact of Delayed Inhibitor Development on Cumulative Breakthrough Bleeds and Costs in Persons with Hemophilia A Receiving Emicizumab Prophylaxis. Blood, 2018, 132, 4710-4710.	0.6	2
80	Emicizumab Prophylaxis Provides Flexible and Effective Bleed Control in Children with Hemophilia Î± with Inhibitors: Results from the HAVEN 2 Study. Blood, 2018, 132, 632-632.	0.6	31
81	Bleeding Severity and Health Care Utilization in Patients with Platelet Function Disorders. Blood, 2018, 132, 4994-4994.	0.6	0
82	von Willebrand disease Outreach into Integrated Care Education (VOICE): a call to action. Haemophilia, 2017, 23, e370-e373.	1.0	3
83	Management of <scp>US</scp> men, women, and children with hemophilia and methods and demographics of the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (Bâ€<scp>HERO</scp>â€S) study. European Journal of Haematology, 2017, 98, 5-17.	1.1	25
84	Evaluating the psychosocial impact of hemophilia B: The Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (Bâ€<scp>HERO</scp>â€S) study. European Journal of Haematology, 2017, 98, 3-4.	1.1	2
85	Impact of diagnosis of von Willebrand disease on patient outcomes: Analysis of medical insurance claims data. Haemophilia, 2017, 23, 743-749.	1.0	22
86	HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors. Blood, 2017, 130, 85-85.	0.6	38
87	Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic anemia. Journal of Pediatric Surgery, 2016, 51, 122-127.	0.8	39
88	Impact of Mild to Severe Hemophilia B on Quality of Life Including Pain and Functional Abilities in Affected Men/Women and Caregivers of Affected Boys/Girls: Analysis of Patient Reported Outcomes in the Bridging Hemophilia B Experiences Results and Opportunities into Solutions (B-HERO-S) Study. Blood, 2016, 128, 251-251.	0.6	1
89	Haemophilia A carriers experience reduced healthâ€related quality of life. Haemophilia, 2015, 21, 761-765.	1.0	29
90	A crossâ€sectional study of bleeding phenotype in haemophilia A carriers. British Journal of Haematology, 2015, 170, 223-228.	1.2	75

#	Article	IF	Citations
91	New developments in pediatric venous thromboembolism and anticoagulation, including the target-specific oral anticoagulants. Current Opinion in Pediatrics, 2015, 27, 18-25.	1.0	13
92	The Use of an Extracorporeal Membrane Oxygenation Anticoagulation Laboratory Protocol Is Associated With Decreased Blood Product Use, Decreased Hemorrhagic Complications, and Increased Circuit Life*. Pediatric Critical Care Medicine, 2015, 16, 66-74.	0.2	105
93	Clinical outcomes of splenectomy in children: Report of the splenectomy in congenital hemolytic anemia registry. American Journal of Hematology, 2015, 90, 187-192.	2.0	33
94	One-Stage FVIII Activity Is Inversely Correlated with Heavy Menstrual Bleeding in Hemophilia a Carriers. Blood, 2015, 126, 3542-3542.	0.6	0
95	Management of VWD. Hematology American Society of Hematology Education Program, 2014, 2014, 536-541.	0.9	16
96	Females with FVIII and FIX deficiency have reduced joint range of motion. American Journal of Hematology, 2014, 89, 831-836.	2.0	43
97	Three Cost-utility Analyses of Screening for Intracranial Hemorrhage in Neonates With Hemophilia. Journal of Pediatric Hematology/Oncology, 2014, 36, 474-479.	0.3	4
98	Both Hemophilia Health Care Providers and Hemophilia A Carriers Report That Carriers Have Excessive Bleeding. Journal of Pediatric Hematology/Oncology, 2014, 36, e224-e230.	0.3	25
99	Rise in Late Onset Vitamin K Deficiency Bleeding in Young Infants Because of Omission or Refusal of Prophylaxis at Birth. Pediatric Neurology, 2014, 50, 564-568.	1.0	105
100	The impact of age and <scp>CYP</scp>2C9 and <scp>VKORC</scp>1 variants on stable warfarin dose in the paediatric population. British Journal of Haematology, 2014, 165, 832-835.	1.2	24
101	A two-center retrospective review of the hematologic evaluation and laboratory abnormalities in suspected victims of non-accidental injury. Child Abuse and Neglect, 2014, 38, 1794-1800.	1.3	12
102	Haemophilia A carriers demonstrate pathological and radiological evidence of structural joint changes. Haemophilia, 2014, 20, e426-9.	1.0	28
103	Idiopathic Myelofibrosis in Children. Journal of Pediatric Hematology/Oncology, 2013, 35, 559-565.	0.3	10
104	Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyurea. Pediatric Blood and Cancer, 2013, 60, 1333-1337.	0.8	34
105	Females With FVIII Deficiency Have Reduced Mean Overall Joint Range Of Motion. Blood, 2013, 122, 3601-3601.	0.6	0
106	Predictors of von Willebrand disease in children. Pediatric Blood and Cancer, 2012, 58, 736-740.	0.8	8
107	Discordance in Provider Practice Patterns and Hemophilia A Carrier Health Care Preferences. Blood, 2012, 120, 3385-3385.	0.6	1
108	Retrospective Review of Hematologic Evaluation in Children with Suspected Non-Accidental Injury, A First Step towards Evidence Based Guidelines.. Blood, 2012, 120, 2231-2231.	0.6	0

#	Article	IF	Citations
109	Screening for von Willebrand disease in children: a case-control study. Journal of Thrombosis and Haemostasis, 2011, 9, 1086-1089.	1.9	5
110	Predictors of Von Willebrand Disease In Children: A Case-Control Study. Blood, 2010, 116, 712-712.	0.6	0
111	Factor VIII Intron 22 Inversion Screening of Newborn Males for Hemophilia A: A Cost-Effectiveness Study. Blood, 2010, 116, 734-734.	0.6	0
112	Cost-Utility Analysis of Von Willebrand Disease Screening in Adolescents with Menorrhagia.. Blood, 2009, 114, 2476-2476.	0.6	7
113	Proteinase expression during differentiation of human osteoclasts in vitro. Journal of Cellular Biochemistry, 2000, 78, 627-637.	1.2	35